Last reviewed · How we verify
Diclofenac sodium and safinamide
Diclofenac sodium and safinamide is a Small molecule drug developed by Zambon SpA. It is currently in Phase 1 development. Also known as: Voltaren and Xadago.
At a glance
| Generic name | Diclofenac sodium and safinamide |
|---|---|
| Also known as | Voltaren and Xadago |
| Sponsor | Zambon SpA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diclofenac sodium and safinamide CI brief — competitive landscape report
- Diclofenac sodium and safinamide updates RSS · CI watch RSS
- Zambon SpA portfolio CI
Frequently asked questions about Diclofenac sodium and safinamide
What is Diclofenac sodium and safinamide?
Diclofenac sodium and safinamide is a Small molecule drug developed by Zambon SpA.
Who makes Diclofenac sodium and safinamide?
Diclofenac sodium and safinamide is developed by Zambon SpA (see full Zambon SpA pipeline at /company/zambon-spa).
Is Diclofenac sodium and safinamide also known as anything else?
Diclofenac sodium and safinamide is also known as Voltaren and Xadago.
What development phase is Diclofenac sodium and safinamide in?
Diclofenac sodium and safinamide is in Phase 1.
Related
- Manufacturer: Zambon SpA — full pipeline
- Also known as: Voltaren and Xadago
- Compare: Diclofenac sodium and safinamide vs similar drugs
- Pricing: Diclofenac sodium and safinamide cost, discount & access